1[1]Jass JR. The origin and nature of pathology[A]. In: Understanding Pathology[M]. Australia:Harwood Academic Publishers, 1999. 3-9.
2[4]Alizadeh AA, Eisen MB, Davis EE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling[J]. Nature, 2000, 403(6769): 503-511.
3[5]Shipp MA, Ross KN, Tamayo P, et al. Diffuse large Bcell lymphoma outcome prediction by gene-expression profiling and supervised machine learning [J]. Nat Med,2002, 8(1): 68-74.
4[6]Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci USA,2001, 98(19): 10869-10874.
5[7]Schnitt SJ. Pharmacopathology: a new spin on an old idea[J]. Am J Surg Pathol, 2003, 27(1): 121-123.
6[8]Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831[J]. J Natl Cancer Inst, 2002,94(11): 855-857.
7[9]Mauro MJ, O'Dwyer M, Heinrich MC, et al. STI571: a paradigm of new agents for cancer therapeutics[J]. J Clin Oncol, 2002, 20(1): 325-334.
8[10]Heinrich MC, Corless CL, Demitri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor[J]. J Clin Oncol, 2003, 21(23): 4342-4349.
9[12]Leonard DGB. The future of molecular pathology[A]. In:Lenard DGB. Diagnostic Molecular Pathology [M]. Philadelphia: Saunders, 2003. 189-196.
同被引文献11
1Sackeet DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't[J]. BMJ, 1996,31(23):71-72.
2Alizadeh AA, Eisen MB, Davis EE, ct al. Distinct types d diffuse huge B-cell lymphoma identified by gene expression profiUng [J]. Nature, 2002, 40(9) :503-511.
3Shipp MA, Ross KN, Tamayo P, et aL Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning [J]. Nat Meal, 2002, 8(1):68-74.
